Xinbo Yang

Xinbo Yang

Auto-generated profile, based on publicly available information

Xinbo Yang

Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York City, New York, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2022 in Nature
Verified
Journal Article
Closed access
PDF file
XYXinbo Yang
Xinbo Yang
LGLee I. Garner
Lee I. Garner
IZIvan V. Zvyagin
Ivan V. Zvyagin
MPMichael A. Paley
Michael A. Paley
EKEkaterina A. Komech
Ekaterina A. Komech
KGK. Christopher Garcia
K. Christopher Garcia

19 March 2026 in Science
Verified
Journal Article
Open access
XCXiaojing Chen
Xiaojing Chen
ZMZhiyuan Mao
Zhiyuan Mao
EKE. Motunrayo Kolawole
E. Motunrayo Kolawole
MPMargherita Persechino
Margherita Persechino
KJKevin M. Jude
Kevin M. Jude
KGK. Christopher Garcia
K. Christopher Garcia
T cells are often weakly responsive to tumor self-antigens because of central tolerance, constraining their ability to eliminate tumors. We exploited mechanical force to engineer a weakly reactive T cell receptor (TCR) specific for a nonmutated tumor-associated antigen (TAA), prostatic acid phosphatase (PAP). We identified a catch-bonding “hotspot” whose mutation enhanced T cell activity by increasing TCR–pMHC (peptide–major histocompatibility complex) bond lifetime while preserving physiological affinities and antigen fine specificities. T cells expressing these engineered TCRs showed vastly superior expansion in the tumor, effector phenotypes, and tumor elimination. Crystal structures and molecular dynamics simulations revealed a single amino acid mutation at the catch-bond hotspot primes the TCR for peptide interaction through water reorganization at the TCR-pMHC interface. Catch-bond engineering is a viable biophysically based strategy for transforming tolerized antitumor T cells into potent TCR–T cell therapy killers.

13 May 2026 in Nature Biotechnology
Verified
Journal Article
Open access
NWNan Wang
Nan Wang
HYHugh Yeh
Hugh Yeh
BLBen Lai
Ben Lai
JPJason Perera
Jason Perera
KJKevin M. Jude
Kevin M. Jude
KGK. Christopher Garcia
K. Christopher Garcia
Predicting T cell receptor (TCR) specificity on the basis of sequence is challenging because TCRs of similar sequence can recognize entirely different antigens, whereas TCRs of different sequence can recognize the same antigens. Here we present a system that integrates high-throughput yeast display with fine-tuned protein language models (pLMs) to generate deep peptide recognition profiles (PRPs) for individual TCRs, each detailing binding against millions of peptides. We provide detailed PRPs for a panel of HLA-B*27:05-restricted TCRs from persons with ankylosing spondylitis and acute anterior uveitis that almost exclusively recognize peptides through CDR3β. pLMs trained on these PRPs outperform AlphaFold3 and tFold-TCR in predicting T cell activation. We discover and validate novel candidate autoantigens, demonstrate that model generalization to new TCRs correlates with functional distance (PRP divergence) rather than sequence similarity and introduce a model-intrinsic uncertainty metric to quantify prediction confidence. This system and its associated PRP datasets offer a scalable approach to mapping TCR recognition, accelerating antigen discovery and guiding TCR engineering.

8 October 2025 in Cancer Discovery
Verified
Journal Article
Open access
NGNofar Gumpert
Nofar Gumpert
Shira SagieShira Sagie
Shira Sagie
CAClaudia Arnedo-Pac
Claudia Arnedo-Pac
TBTomer Babu
Tomer Babu
CWChen Weller
Chen Weller
YSYardena Samuels
Yardena Samuels
New approaches that generate long-lasting therapeutic responses in patients with therapy-resistant metastatic cancer are urgently needed. To address this challenge, we developed Spot Neoantigens in Metastases (SpotNeoMet), a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients. We identified seven therapy resistance mutations predicted to produce neopeptides presented by common HLAs. Using HLA immunopeptidomics, we discovered three novel neopeptides derived from androgen receptor (AR) H875Y, a common metastatic castration-resistant prostate cancer (mCRPC) mutation. We validated these neoantigens as highly immunogenic and then isolated and characterized cognate T-cell receptors (TCR) from healthy donor peripheral blood mononuclear cells. We demonstrated that AR H875Y–specific TCRs are highly specific and kill prostate cancer cells presenting AR neopeptides in vitro and in vivo. Our new pipeline identifies novel immunotherapy targets and potential treatment options for patients with mCRPC. Moreover, SpotNeoMet offers a systematic route to identify “HLA–peptide” pairs and their cognate TCRs across treatment-resistant cancers. Significance: As the emergence of resistance to targeted treatments in patients with metastatic cancer, there is an urgent need for innovative therapeutic approaches for this population. Our study provides a new analytic framework to identify neoantigens from treatment-resistant mutations and a proof-of-concept T cell–based immunotherapy treatment for mCRPC.

6 February 2026
Verified
Other
Open access
NGNofar Gumpert
Nofar Gumpert
Shira SagieShira Sagie
Shira Sagie
CAClaudia Arnedo-Pac
Claudia Arnedo-Pac
TBTomer Babu
Tomer Babu
CWChen Weller
Chen Weller
YSYardena Samuels
Yardena Samuels
Specific AR H875Y TCR cytotoxicity in healthy donor PBMCs

6 February 2026
Verified
Other
Open access
NGNofar Gumpert
Nofar Gumpert
Shira SagieShira Sagie
Shira Sagie
CAClaudia Arnedo-Pac
Claudia Arnedo-Pac
TBTomer Babu
Tomer Babu
CWChen Weller
Chen Weller
YSYardena Samuels
Yardena Samuels
Cancer types and sample numbers in the Hartwig cohort